miltenyi sars-cov-2 peptide Price and Review,PepTivator SARS-CoV-2 Prot_S

The ongoing global health landscape necessitates robust tools for understanding and combating viral threats. In the realm of SARS-CoV-2 research, precisely designed peptide products are proving instrumental in dissecting the intricacies of the immune response. Miltenyi Biotec, a leader in cell and gene therapy solutions, offers a comprehensive suite of PepTivator SARS-CoV-2 peptide products, empowering researchers to investigate T cell immunity following infection or vaccination. These peptide pools are meticulously crafted to stimulate T cells reactive to various viral components, providing critical insights into immune memory and potential therapeutic avenues.

A cornerstone of Miltenyi's offering is the PepTivator SARS-CoV-2 Prot_S line, specifically designed to target the spike protein of the SARS-CoV-2 virus. This protein is a primary target for neutralizing antibodies and is crucial for viral entry into host cells. The PepTivator SARS-CoV-2 Prot_S Complete product, for instance, covers the whole protein coding sequence of the surface or spike glycoprotein (S), spanning amino acids 5–1273. This extensive coverage ensures a comprehensive analysis of T cell responses against the entire spike protein. For researchers focusing on specific regions, PepTivator SARS-CoV-2 Prot_S1 is available, targeting the N-terminal S1 domain, while PepTivator SARS-CoV-2 Prot_S+ focuses on a specific domain within the spike protein (aa 689–895). Furthermore, Miltenyi offers specialized PepTivator SARS-CoV-2 Prot_S variants that stimulate T cells reactive to the spike protein of the BA.1, BA.2, BA.4/BA.5 variant of the SARS-CoV-2 B.1.1.529 lineage, commonly known as the Omicron variant. This is crucial for understanding immune responses against emerging viral strains.

Beyond the spike protein, Miltenyi also provides tools to investigate T cell responses against other critical viral components. The PepTivator SARS-CoV-2 Prot_N product targets the nucleoprotein (N) of SARS-CoV-2, another immunodominant antigen. The PepTivator SARS-CoV-2 Prot_M product focuses on the membrane glycoprotein (M) of SARS-CoV-2. These diverse peptide pools allow for a holistic understanding of cellular immunity against the virus.

The PepTivator SARS-CoV-2 peptide products are characterized by their format: PepTivators are pools of lyophilized peptides. They are primarily composed of 15-mer sequences with an 11-amino acid overlap, a design optimized for efficient T cell stimulation. This format ensures that a broad spectrum of T cell epitopes within the target protein are presented. For instance, PepTivator SARS-CoV-2 Select is a specific offering that comprises a peptide pool of 88 lyophilized oligopeptides, derived from the entire proteome of SARS-CoV-2. This pool includes both MHC class I and class II-restricted peptides, enabling the stimulation of both CD8+ and CD4+ T cells. To further enhance research capabilities, PepTivator SARS-CoV-2 MHC-I is available, specifically designed to stimulate CD8+ T cells reactive to SARS-CoV-2. These MHC-I specific PepTivators are also pools of lyophilized peptides.

The application of these peptide products is multifaceted. They are invaluable for researchers aiming to stimulate T cells reactive to the spike protein of the SARS-CoV-2 Wuhan wild-type, providing a baseline for understanding immune responses. Furthermore, SARS-CoV-2 PepTivator Peptide Pools are explicitly designed to investigate T cell immunity in COVID-19 patients, whether acquired through natural infection or vaccination. This is critical for assessing the durability and breadth of immune protection.

The scientific community is actively exploring the immunogenic potential of selected peptides from SARS-CoV-2. Studies utilizing these peptide products contribute to a deeper understanding of viral immunity. The ability to load antigen-presenting cells and stimulate SARS-CoV-2–specific T cells using these peptide pools is a significant advancement in COVID-19 research. The development of two lyophilized mixtures of peptides from SARS-CoV-2 for activating antigen-specific immune cells underscores the commitment to providing comprehensive solutions. Beyond SARS-CoV-2, Miltenyi’s expertise extends to other coronaviruses, with a portfolio that includes peptides for SARS-CoV, MERS, and common cold viruses like CoV 229E and OC43, highlighting a broader commitment to coronavirus research.

The versatility of Miltenyi’s peptide offerings is further exemplified by specialized products. For instance, MACSpep SARS-CoV-2 N utilizes peptides that **cover a broad range